PASQUINI, Silvia
 Distribuzione geografica
Continente #
NA - Nord America 3.195
AS - Asia 2.282
EU - Europa 1.086
SA - Sud America 450
Continente sconosciuto - Info sul continente non disponibili 145
AF - Africa 64
OC - Oceania 10
Totale 7.232
Nazione #
US - Stati Uniti d'America 3.054
SG - Singapore 833
IT - Italia 444
CN - Cina 442
BR - Brasile 367
VN - Vietnam 285
HK - Hong Kong 192
DE - Germania 130
BD - Bangladesh 123
GB - Regno Unito 87
FR - Francia 84
CA - Canada 82
TR - Turchia 67
JP - Giappone 64
IN - India 63
ID - Indonesia 61
RU - Federazione Russa 53
SE - Svezia 51
FI - Finlandia 45
PL - Polonia 45
UA - Ucraina 36
AR - Argentina 32
MX - Messico 32
NL - Olanda 24
ZA - Sudafrica 24
PK - Pakistan 19
TW - Taiwan 19
CH - Svizzera 17
IQ - Iraq 16
ES - Italia 15
MY - Malesia 14
CO - Colombia 13
MA - Marocco 13
SA - Arabia Saudita 12
EC - Ecuador 11
AT - Austria 10
KE - Kenya 10
KR - Corea 10
LT - Lituania 10
AU - Australia 9
UZ - Uzbekistan 9
VE - Venezuela 8
BE - Belgio 7
TN - Tunisia 7
PH - Filippine 6
PY - Paraguay 6
BH - Bahrain 5
CL - Cile 5
CR - Costa Rica 5
IR - Iran 5
JM - Giamaica 5
JO - Giordania 5
AE - Emirati Arabi Uniti 4
EG - Egitto 4
IL - Israele 4
NP - Nepal 4
PT - Portogallo 4
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
HN - Honduras 3
KZ - Kazakistan 3
LV - Lettonia 3
PA - Panama 3
PS - Palestinian Territory 3
UY - Uruguay 3
BG - Bulgaria 2
BO - Bolivia 2
CI - Costa d'Avorio 2
ET - Etiopia 2
EU - Europa 2
GE - Georgia 2
GT - Guatemala 2
HU - Ungheria 2
IE - Irlanda 2
KG - Kirghizistan 2
PE - Perù 2
RS - Serbia 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CY - Cipro 1
DK - Danimarca 1
GD - Grenada 1
GP - Guadalupe 1
GR - Grecia 1
GY - Guiana 1
KH - Cambogia 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
MR - Mauritania 1
MT - Malta 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
Totale 7.084
Città #
Ashburn 542
Singapore 514
San Jose 259
Hong Kong 188
Santa Clara 171
Council Bluffs 169
Fairfield 166
Beijing 163
Woodbridge 107
Los Angeles 106
Chandler 104
Ho Chi Minh City 96
Ferrara 92
Houston 91
New York 88
Seattle 74
Hanoi 66
Munich 61
Tokyo 59
Cambridge 55
Jakarta 53
Milan 52
Dallas 50
Lauterbourg 48
Wilmington 48
Warsaw 41
São Paulo 38
Ann Arbor 37
Shanghai 34
Orem 33
Buffalo 31
Toronto 30
Bologna 29
Jacksonville 29
Izmir 28
Princeton 27
Denver 25
Chennai 22
Chicago 22
London 22
Montreal 19
Phoenix 18
Turku 18
Frankfurt am Main 17
Mexico City 16
Hefei 15
Helsinki 15
Rio de Janeiro 15
Zurich 15
Atlanta 14
Da Nang 14
Manchester 14
Taipei 14
Rome 13
Johannesburg 12
Poplar 12
Boston 11
Brooklyn 11
Haiphong 11
Nanjing 11
Nuremberg 11
San Francisco 11
Ankara 10
Florence 10
Kuala Lumpur 10
San Diego 10
Venice 10
Boardman 9
Falls Church 9
Moscow 9
Tucson 9
Vercelli 9
Curitiba 8
Ferrara di Monte Baldo 8
Istanbul 8
Naples 8
Nice 8
Salt Lake City 8
Tashkent 8
Belo Horizonte 7
Columbus 7
Genoa 7
Nairobi 7
Salvador 7
San Antonio 7
Stockholm 7
Baghdad 6
Biên Hòa 6
Brussels 6
Charlotte 6
Goiânia 6
Hải Dương 6
Nanchang 6
Newark 6
Ottawa 6
The Dalles 6
Tianjin 6
Verona 6
Blumenau 5
Bắc Ninh 5
Totale 4.459
Nome #
Positive allosteric modulation of A1 adenosine receptors as a novel and promising therapeutic strategy for anxiety 304
Pulsed Electromagnetic Field Exposure Reduces Hypoxia and Inflammation Damage in Neuron-Like and Microglial Cells 269
The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity profiles 257
Role and function of A2A and A3 adenosine receptors in patients with ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis 245
The role of adenosinergic system in brain ischemia 245
Adenosine Receptors as a Biological Pathway for the Anti-Inflammatory and Beneficial Effects of Low Frequency Low Energy Pulsed Electromagnetic Fields 216
Design, Synthesis, and Pharmacological Characterization of Indol-3-ylacetamides, Indol-3-yloxoacetamides, and Indol-3-ylcarboxamides: Potent and Selective CB2 Cannabinoid Receptor Inverse Agonists 209
A2A Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer's Disease 188
Development of novel pyridazinone-based adenosine receptor ligands 186
A2A Adenosine Receptor: A Possible Therapeutic Target for Alzheimer's Disease by Regulating NLRP3 Inflammasome Activity? 182
A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma 177
Amino-3, 5-dicyanopyridines targeting the adenosine receptors ranging from pan ligands to combined A1/A2B partial agonists 169
Caffeine for Prevention of Alzheimer's Disease: Is the A2A Adenosine Receptor Its Target? 164
Development of Epigenetic Modifiers with Therapeutic Potential in FMS-Related Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Acute Myeloid Leukemia and Other Blood Malignancies 163
Development of potent and selective FAAH inhibitors with improved drug-like properties as potential tools to treat neuroinflammatory conditions 162
Adenosine and inflammation: Here, there and everywhere 162
A1 Adenosine Receptor Partial Agonists and Allosteric Modulators: Advancing Toward the Clinic? 157
Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity 152
2-Amino-5-arylethynyl-thiophen-3-yl-(phenyl)methanones as A1 Adenosine Receptor Positive Allosteric Modulators 150
4-Heteroaryl Substituted Amino-3,5-Dicyanopyridines as New Adenosine Receptor Ligands: Novel Insights on Structure-Activity Relationships and Perspectives 149
Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic Targets 147
Pathophysiological Role and Medicinal Chemistry of A2A Adenosine Receptor Antagonists in Alzheimer's Disease 144
Pharmacology of Adenosine Receptors: Recent Advancements 140
Effect of Low-Frequency, Low-Energy Pulsed Electromagnetic Fields in Neuronal and Microglial Cells Injured with Amyloid-Beta 139
Synthesis of Unsymmetrical Squaramides as Allosteric GSK-3β Inhibitors Promoting β-Catenin-Mediated Transcription of TCF/LEF in Retinal Pigment Epithelial Cells 139
An Open Question: Is the A2A Adenosine Receptor a Novel Target for Alzheimer's Disease Treatment? 138
A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patients 135
Adenosinergic System Involvement in Ischemic Stroke Patients' Lymphocytes 135
The Detrimental Action of Adenosine on Glutamate-Induced Cytotoxicity in PC12 Cells Can Be Shifted towards a Neuroprotective Role through A1AR Positive Allosteric Modulation 135
Spirotetrahydroisoquinoline-Based Histone Deacetylase Inhibitors as New Antifibrotic Agents: Biological Evaluation in Human Fibroblasts from Bronchoalveolar Lavages of Idiopathic Pulmonary Fibrosis Patients 134
Pulsed Electromagnetic Field Stimulation in Osteogenesis and Chondrogenesis: Signaling Pathways and Therapeutic Implications 129
Are Two Riboses Better Than One? The Case of the Recognition and Activation of Adenosine Receptors 127
Targeting Relevant HDACs to Support the Survival of Cone Photoreceptors in Inherited Retinal Diseases: Identification of a Potent Pharmacological Tool with In Vitro and In Vivo Efficacy 126
Pioneering first-in-class FAAH-HDAC inhibitors as potential multitarget neuroprotective agents 124
Binding and unbinding of potent melatonin receptor ligands: Mechanistic simulations and experimental evidence 123
Update on the recent development of allosteric modulators for adenosine receptors and their therapeutic applications 120
Strategies for Drug Delivery into the Brain: A Review on Adenosine Receptors Modulation for Central Nervous System Diseases Therapy 119
Identification of novel thiazolo[5,4-d]pyrimidine derivatives as human A1and A2A adenosine receptor antagonists/inverse agonists 116
Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition 116
Cytotoxic and Antiproliferative Effects of [64Cu]CuCl2 in Tumor Cells for Radiometabolic Therapy: a Preliminary Study 113
Structure-activity relationship studies and pharmacological characterization of N5-heteroarylalkyl-substituted-2-(2-furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine-based derivatives as inverse agonists at human A2Aadenosine receptor 109
Reversing TGF-β1-induced fibrotic phenotype in human lung fibroblasts using a PROTAC tool derived from an indoline-based HDAC6 inhibitor 105
Structural investigation on thiazolo[5,4-d]pyrimidines to obtain dual-acting blockers of CD73 and adenosine A2A receptor as potential antitumor agents 104
Pulsed electromagnetic fields stimulate hif-1α-independent vegf release in 1321n1 human astrocytes protecting neuron-like sh-sy5y cells from oxygen-glucose deprivation 101
Targeting adenosine receptors: A potential pharmacological avenue for acute and chronic pain 93
Piperazine-and piperidine-containing thiazolo[5,4-d]pyrimidine derivatives as new potent and selective adenosine a2a receptor inverse agonists 84
Targeting Class I Histone Deacetylases Triggers Antitumor Responses in Colorectal Cancer In Vitro and In Vivo 57
Cytotoxic and Antiproliferative Effects of [64Cu]CuCl2 in Tumor Cells for Radiometabolic Therapy 55
In Vitro Radiobiological Evaluation of [64Cu]CuCl2 for Theranostic Applications 12
Colorectal Cancer: A Landscape of New Potential Radiopharmaceuticals 7
Totale 7.232
Categoria #
all - tutte 35.907
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.907


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022218 0 14 13 0 5 17 27 20 16 18 44 44
2022/2023286 29 48 4 27 23 20 43 22 24 9 23 14
2023/2024235 17 14 9 6 38 13 11 24 7 13 10 73
2024/20251.440 39 62 116 58 127 149 104 88 226 163 170 138
2025/20263.926 372 186 307 460 568 217 414 237 325 453 225 162
2026/2027286 156 130 0 0 0 0 0 0 0 0 0 0
Totale 7.232